Abstract: The invention concerns a method for monitoring the operating state of a system for positioning variable-geometry members (18) of a turbomachine (10), the members (18) being configured to travel over an operating area comprising a first position P1 and a second position P2, the method comprising the steps of: —(E23) determining a first pivoting speed V1 from the first position P1 to the second position P2; —(E25) determining a second pivoting speed from the second position P2 to the first position P1; and—(E26) determining an anomaly in the operation of the system for positioning the members (18) if the first speed V1 is lower than a first determined speed threshold and/or if the second speed V2 is lower than a second determined speed threshold.

Abstract: An emergency oxygen system for aircraft comprising: a breathing gas supply circuit to be connected upstream to a source of breathing gas and downstream to at least one mask, a flow control valve configured to adjust the flow of breathing gas supplied to the mask, an electronics board configured to control the flow control valve, a power source, a switching device interposed between the power source and the electronics board, the switching device comprising a switch configured to have a first state in which power from the power source is supplied to the electronics board and a second state in which the electronics board is not supplied with power from the power source.

Abstract: A system for delivering breathing gas to passengers includes: a face mask including a face part having a breathing cavity, a tube configured to be supplied by pressurized breathing gas, and a reservoir bag disposed between the tube and the face part. A passage connects the reservoir bag to the breathing cavity so that the system is configured to supply the breathing cavity through the reservoir bag. The reservoir bag includes a front portion and a back portion. The front portion is connected to the face mask, and the system has a stowed configuration and a deployed configuration. In the stowed configuration, the reservoir bag is maintained folded between a backing and the face part.

Abstract: A system for delivering breathing gas to passengers on-board an aircraft, including: a source of breathing gas, at least one face mask for passengers, a reservoir associated with each face mask, a delivery valve for each face mask, the delivery valve being disposed between the source of breathing gas and the reservoir, the reservoir being disposed between the delivery valve and the face mask, a sensor associated with each reservoir and configured to sense a filling of the reservoir, and a controller configured to control the delivery valve in a continuous supply mode to provide a continuous flow of breathing gas to the reservoir and to interrupt the continuous flow of breathing gas when the filing sensed by the sensor is a filling threshold.

Abstract: An emergency oxygen system for aircraft comprising: a breathing gas supply circuit to be connected upstream to a source of breathing gas and downstream to at least one mask, a flow control valve configured to adjust the flow of breathing gas supplied to the mask, an electronics board configured to control the flow control valve, a power source, a switching device interposed between the power source and the electronics board, the switching device comprising a switch configured to have a first state in which power from the power source is supplied to the electronics board and a second state in which the electronics board is not supplied with power from the power source.

Abstract: A system for delivering breathing gas to passengers on-board an aircraft, comprising: a source of breathing gas, at least one face mask for passengers, a reservoir associated with each face mask, a delivery valve for each face mask, the delivery valve being disposed between the source of breathing gas and the reservoir, the reservoir being disposed between the delivery valve and the face mask, a sensor associated with each reservoir and configured to sense a filling of the reservoir, and a controller configured to control the delivery valve in a continuous supply mode to provide a continuous flow of breathing gas to the reservoir and to interrupt the continuous flow of breathing gas when the filing sensed by the sensor is a filling threshold.

Abstract: The present invention concerns a new general process for asymmetric hemisynthesis of harringtonines and their analogs, that are alkaloids used in chemotherapy. This process comprises direct esterification of a natural cephalotaxine with an acylating compound constituted of a side chain precursor which backbone and functionalization are entirely preformed. The invention also concerns a natural, synthetic or semi-synthetic harringtonines including their tautomeric forms and their salts of the following formula: wherein n=2 (i.e. harringtonine) or n=3 (i.e. homoharringtonine), in which the total content of impurities, possibly including enantiomeric forms, is lower than 1%, and/or the content of the major impurity is lower than 0.9%, and/or the chromatographic assay exhibits a harringtonines content higher than 97.5%.

Abstract: The present invention relates to an isolated cell capable of fixing tumour cells, expressing the CD10 protein and expressing at least one MDR protein, and to the use of this cell for screening for anti-tumour compounds.

Abstract: The present invention concerns a compound of formula (I) wherein: W represents O or NH, Q represents an unbranched or branched, saturated or unsaturated or aromatic, cyclic or acyclic or heterocyclic hydrocarbon radical containing 1 to 30 carbon atoms including or not heteroatom(s), R1 is H, OH, or R1, R2 form together —O—, R3?R4?OMe or R3 and R4 form together —OCH2O—, R is H, C1-C30alkyl or O-protecting group and R6 represents an unbranched or branched, saturated or unsaturated or aromatic, cyclic or acyclic or heterocyclic hydrocarboned radical containing 1 to 30 carbon atoms including or not heteroatom(s), or R and R6 form together —CMe2-, n is 0 to 8, R5 is H, OH, OMe, O—(C1-C30)-alkyl, O-aryl-(C1-C30)-alkyl, O—(C2-C30)-alkenyl, O—(C3-C30)-cycloalkyl or O-aryl, the dotted line is null or forms a double bond depending on the meaning of R1. It also concerns their methods of preparation and their use in treatment of cancers, leukemias, parasites and as reversal agents of harringtonines.

Abstract: The present invention concerns a new general process for asymmetric hemisynthesis of harringtonines and their analogs, that are alkaloids used in chemotherapy. This process comprises direct esterification of a natural cephalotaxine with an acylating compound constituted of a side chain precursor which backbone and functionalization are entirely preformed. The invention also concerns a natural, synthetic or semi-synthetic harringtonines including their tautomeric forms and their salts of the following formula: wherein n=2 (i.e. harringtonine) or n=3 (i.e. homoharringtonine), in which the total content of impurities, possibly including enantiomeric forms, is lower than 1%, and/or the content of the major impurity is lower than 0.9%, and/or the chromatographic assay exhibits a harringtonines content higher than 97.5%.

Abstract: The present invention concerns a new general process for asymmetric hemisynthesis of harringtonines and their analogs, that are alkaloids used in chemotherapy. This process comprises direct esterification of a natural cephalotaxine with an acylating compound constituted of a side chain precursor which backbone and functionalization are entirely preformed. The invention also concerns a natural, synthetic or semi-synthetic harringtonines including their tautomeric forms and their salts of the following formula: wherein n=2 (i.e. harringtonine) or n=3 (i.e. homoharringtonine), in which the total content of impurities, possibly including enantiomeric forms, is lower than 1%, and/or the content of the major impurity is lower than 0.9%, and/or the chromatographic assay exhibits a harringtonines content higher than 97.5%.

Abstract: The invention concerns a natural, synthetic or semi-synthetic harringtonines including their tautomeric forms and their salts of the following formula: wherein n=2 (i.e. harringtonine) or n=3(i.e. homoharringtonine), in which the total content of impurities, possibly including enantiomeric forms, is lower than 1%, and/or the content of the major impurity is lower than 0.9%, and/or the chromatographic assay exhibits a harringtonines content higher than 97.5%.

Abstract: The present invention concerns a compound of formula (I) 1

Abstract: The present invention concerns a compound of formula (I) wherein: W represents O or NH, Q represents an unbranched or branched, saturated or unsaturated or aromatic, cyclic or acyclic or heterocyclic hydrocarbon radical containing 1 to 30 carbon atoms including or not heteroatom(s), R1 is H, OH, or OMe, O-(C1-C30)-alkyl, O-aryl-(C1-C30)-alkyl, O-(C2-C30)-alkenyl, O-(C3-C30)-cycloalkyl or null, and R2 is H or OH, or R1 and R2 form together —O—, R3=R4=OMe or R3 and R4 form together —OCH2O—, R is H, C1-C30 alkyl or O-protecting group and R6 represents an unbranched or branched, saturated or unsaturated or aromatic, cyclic or acyclic or heterocyclic hydrocarbon radical containing 1 to 30 carbon atoms including or not heteroatom(s), or R and R6 form together —CMe2—, n is 0 to 8, R5 is H, OH, OMe, O-(C1-C30)-alkyl, O-aryl-(C1-C30)-alkyl, O-(C2-C30)-alkenyl, O-(C3-C30)-cycloalkyl or O-aryl, the dotted line is null or forms a double bond dep

Abstract: A new method of therapy using the subcutaneous mode of administration of formulations based upon harringtonines including their salts and tautomeric forms having the formula 1

Abstract: A linked multilayer woven fabric for use in the production of structural composite materials has a base weave comprising twenty-eight weft yarns which are distributed in eight columns containing alternately four superimposed yarns and three superimposed yarns such that they are in a staggered arrangement on seven levels, and twelve warp yarns which are arranged in four parallel planes each containing three superimposed parallel warp yarns.

Abstract: The present invention concerns a new general process for asymmetric hemisynthesis of harringtonines and their analogs, that are alkaloids used in chemotherapy. This process comprises direct esterification of a natural cephalotaxine with an acylating compound constituted of a side chain precursor which backbone and functionalization are entirely preformed. The invention also concerns a natural, synthetic or semi-synthetic harringtonines including their tautomeric forms and their salts of the following formula: wherein n=2 (i.e. harringtonine) or n=3 (i.e. homoharringtonine), in which the total content of impurities, possibly including enantiomeric forms, is lower than 1%, and/or the content of the major impurity is lower than 0.9%, and/or the chromatographic assay exhibits a harringtonines content higher than 97.5%.